Take control of your epilepsy and seizures. Seizure management has never been easier.
TAKE CONTROL TODAY
Epilepsy Therapy Project Announces "Shark Tank" Winner with
Most Innovative Product
The Epilepsy Therapy Project (ETP), a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and the parent organization of epilepsy.com, today released presentation highlights from its successful 2012 Epilepsy Pipeline Update Conference held in San Francisco and announced the winner of its "Shark Tank" competition for the most innovative new product idea in epilepsy treatment and care. This year's epilepsy pipeline conference featured a stellar line up of leading drug and device developers, investigators and industry leaders and showcased cutting-edge epilepsy therapies in development, including medical technology and therapeutic products.
The winner of ETP's inaugural "Shark Tank" competition is Charles Anderson of HiPass Design for his Smartphone-based Movement Detector, a life-saving seizure alarm. Anderson's invention was inspired from a personal concern that he was unable to detect his son's seizures at night. Anderson first devised a computer system that analyzed images from an infrared camera and detected seizure movements with few false alarms. The prototype system, which incorporates an iPhone with camera, sounds an alarm while recording valuable video and audio information. ETP Shark Tank judges and audience participants – representative of industry, advocacy, investors, the research and medical communities – selected this advanced seizure movement detector among the finalists as the most innovative, and for its near-term benefit for people with epilepsy. Anderson received a $50,000 grant to support and accelerate the development and commercialization of this seizure alarm, which is expected to be available later in the year.
The 2012 Epilepsy Therapy Pipeline Conference programs featured some of the most innovative epilepsy therapies and products in development today including:
Companies selected to present their epilepsy product and product candidate programs included NeuroAdjuvants, Inc., NeuroTherapeutics Pharma, Catalyst Pharmaceutical Partners, Inc., Concert Pharmaceuticals, NeuroGenomeX, Inc., Asklepios BioPharmaceutical, Inc., Upsher-Smith Laboratories, Electrical Geodesics, Inc., Advanced Neurometrics, Inc., SynapCell SAS, NeuroPace, Inc., Cyberonics, Inc., Medtronic Neuromodulation Research, , Sunovion Pharmaceuticals, Inc., UCB BioSciences, Inc., Lundbeck, US, Pfizer, Inc., Marinus Pharmaceuticals, Inc., SK LifeScience, Inc. and Supernus Pharmaceuticals, Inc.
"Through this conference and ETP's funding efforts, we are identifying, advocating for and accelerating highly competitive pipeline programs and inventive ideas through development and to the patient," said Warren Lammert, ETP Founder and Chairman. "ETP concentrates on important new therapies with near-term potential to improve the lives of people living with epilepsy today. We also have the unique flexibility to 'take chances' on high-risk high-gain projects, and advance the most valuable new products closer to commercialization. ETP is proud to be a supporter of several of the novel therapies and products presented at this year's conference."
2012 ETP Lifetime Accelerator Award
Harvey Kupferberg, Ph.D., was honored at this year's pipeline conference as the recipient of the ETP Lifetime Accelerator Award in recognition of his commitment and contributions to the field of epilepsy and to the people affected by it. Dr. Kupferberg served for many years as Chief of the Preclinical Pharmacology Section, Epilepsy Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health. He played an essential role in the NINDS Antiepileptic Drug Development (ADD) program which conducts preclinical studies of promising new drugs for the treatment of epilepsy. The program supports drug screening that significantly shortens industry's time for developing new antiepileptic drugs. Dr. Kupferberg developed the program, which has screened thousands of compounds for their potential in treating seizures
About the Epilepsy Pipeline Update Conference
The Third Biennial Epilepsy Pipeline Update Conference 2012 was held at the Hyatt Regency in San Francisco. This conference has earned recognition as the leading showcase for the most promising epilepsy therapies in development from entrepreneurs, startups and established companies dedicated to pioneering and advancing drugs, biologics, technologies and devices for epilepsy. This year's conference was expanded to three days to include the inaugural "Shark Tank" competition, and a day of public programming for people with epilepsy, family and healthcare advocates focused on the importance and challenges of developing new therapies for epilepsy and seizure conditions.
Led by some of the nation's leading experts and advisors on epilepsy.com, the public forum featured panels such as "New Ways of Understanding the Brain and Epilepsy" and "Epilepsy Medications and Alternative Therapies on the Horizon," as well as a discussion of "SUDEP (Sudden Unexplained Death in Epilepsy): What do We Know and What We Need to Talk About." The program also included presentations on dietary therapies, insights from people with epilepsy, tools that can be used in managing epilepsy and more. ETP spokespeople and special guests USA Olympic Hockey Team goaltender Chanda Gunn and L.A. celebrity turntable artist DJ Hapa inspired others with their own stories of living with epilepsy and overcoming many of the challenges. For more information on the conference program and presentations, please visit www.epilepsy.com.
About the Epilepsy Therapy Project The Epilepsy Therapy Project is a 501(c) (3) non-profit organization whose mission is to accelerate ideas into therapies for people living with epilepsy and seizures. Founded in 2002 by a group of parents, distinguished physicians, and researchers, the Epilepsy Therapy Project supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects.
The Epilepsy Therapy Project is a 501 (c) (3) not-for-profit corporation dedicated to a singular focus: overcoming the funding gaps and roadblocks that slow the progress of new therapies from the lab to the patient. Epilepsy Therapy Project seeks to improve incentives and encourage commercial investment in new therapies. Acting as both a catalyst and clearing house for innovative research and the early commercialization of new therapies, the Epilepsy Therapy Project brings together financial resources, scientific insights and business expertise from leading academic and commercial industry participants.
Epilepsy Therapy Project has raised more than $6 million towards its mission.
The story of the Epilepsy Therapy Project, its founding in 2002 by parents of young children living with severe epilepsy, and the programs and therapies we have supported. Read more
Our MissionLearn about the Epilepsy Therapy Project's mission, and why we need your help. Read more
Who We AreTo invest your contributions effectively, we have assembled an outstanding staff and team of clinicians, researchers, and pharmaceutical, biotechnology, and finance industry advisors. These scientific and business advisory board members make funding decisions and provide support to advance the most promising new therapy projects. Meet our team
epilepsy.comEpilepsy.com is a dynamic online resource providing in-depth information and community for people living with epilepsy, and is the home of the Epilepsy Therapy Project. The mission of epilepsy.com is to inform and empower patients and families facing newly diagnosed epilepsy or those struggling with epilepsy that has resisted treatment. Read more
epilepsy.com professionalsAn online resource for healthcare professionals to learn about epilepsy and seizures, co-existing disorders, specialized populations, and diagnosis and treatment for epilepsy. Visit our site for daily research and medical news about epilepsy, commentary from leading voices in the field, and opinions on controversial topics surrounding epilepsy research and treatment. Read more
A Message from Our Chairman and Co-Founder
Keeping a promise, and with thanks and appreciation, Warren Lammert, Chairman and Co-Founder offers some highlights of the Epilepsy Therapy Project's important accomplishments and progress. Read more
Annual ReportReflecting on the year behind us, this report features some of the programs that are supported through your contributions. Read more
The Epilepsy Therapy Project supports innovative research in both academic and industry settings through direct grants and investments. Learn about our programs and how the Epilepsy Therapy Project is supporting research and helping to advance new therapies.
New Therapy - Commercialization Grants / Apply for Grant Funding
The New Therapy - Commercialization Grants Program is a unique partnership between two leading epilepsy non-profit organizations, the Epilepsy Therapy Project and the Epilepsy Foundation. The mission of the New Therapy - Commercialization Grants Program is to drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. Funding is provided to academic and commercial groups worldwide. The Program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. The Program also encourages 1:1 matching grants to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. Preference will be given to proposals that already have a commercial partner engaged to assist with development, and to proposals that have committed or matched funding from a sponsoring institution, commercial partner or other third party source. Read more
Funding Portfolio
The Epilepsy Therapy Project directly supports promising new therapies and emerging epilepsy focused companies through research awards and equity investments. Review the list of funded projects and investments in this section. Read more
Other Sources of Funding
View the list of additional funding sources here. Read more
Learn more about the Epilepsy Therapy Project's upcoming events!
Epilepsy Therapy Project's past events
PharmaVoice highlights the story of ETP Founder and Chair, Warren Lammert and his daughter, Sylvie, who has uncontrolled seizures. Sylvie inspired Warren, Sylvie’s mother Kathy, and colleagues to initiate the Epilepsy Therapy Project, to accelerate development of new therapies for epilepsy. Read the story
| Chairman's Corner | |
|---|---|
| A Job Well Done - Ode to Robert Fisher and Hearty Welcome to Joe Sirven | 10/04/2010 |
| Epilepsy Pipeline Wiki: Time to make it happen | 10/03/2010 |
| Don't miss Epilepsy Talk Radio or the new Epilepsy Diary | 4/25/2010 |
| Sylvie turns 13. Shadow of 2 seizures on that special day | 3/31/2010 |
| A Year in Review - Happy Holidays from the Epilepsy Therapy Project | 12/17/2009 |
| Our new "My Epilepsy Diary" is live... | 8/27/2009 |
Start Your Own Epilepsy Group
Get connected and stay connected! Create a virtual meeting place for
your organization or an existing epilepsy research group and deepen your
connections using the Group Event Calender, Group Discussions and Shared
Member Blogs.
Learn
More

